Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Figure 1 A B C CD56 D E F CD56.

Published byDaria Sowińska Modified over 5 years ago

Similar presentations

Presentation on theme: "Supplementary Figure 1 A B C CD56 D E F CD56."— Presentation transcript:

1 Supplementary Figure 1 A B C CD56 D E F CD56

2 LCNEC 68c PIK3CA_E545K LCNEC 13c PTEN_S59* G A T C A LCNEC 9c
Supplementary Figure 2 LCNEC 68c PIK3CA_E545K LCNEC 13c PTEN_S59* G A T C A LCNEC 9c PTEN_K342* T G C T C A C T G A G C A G A LCNEC 11p MTOR_E2419K LCNEC 4c RICTOR_R910H G G C T T C C A G C A G T G T A C G A A C A T T

3 OCP: Oncomine® Cancer Research Panel
Supplementary Figure 3 Sample Gene symbol Target Seq. OCP Copy number LCNEC 72C FGFR1 20.3 20.6 LCNEC 42C MYCL1 10.5 11.5 LCNEC 1p MYCN 18.3 22.3 KIT 8.0 6.7 PDGFRA 7.2 LCNEC 9p KRAS 28.2 23.9 MYC 16.7 21.3 SCLC_106C 7.8 8.7 SCLC_187C 10.9 11.6 SCLC_143C 52.5 84.3 OCP 84 53 (Copy number) (Copy number) Target Sequence OCP: Oncomine® Cancer Research Panel LCNEC: large cell neuroendocrine carcinoma, SCLC: small cell lung cancer

4 Supplementary Figure 4 MYC MYCL1 FGFR1

5 Supplementary Figure 5 RTKs: receptor tyrosine kinases female
Sex Smoking History Advanced Case　 Symbol n PI3K/AKT/mTOR pathway MYC family MAPK/ERK pathway Major RTKs Others PI3K /AKT /mTOR pathway PIK3CA 5 PTEN 8 AKT2 3 RICTOR MTOR MYC MYCL1 6 MYCN MAPK　/ERK pathway KRAS HRAS MAP2K1 1 MAP2K2 NF1 4 FGFR1 KIT 2 ERBB2 ROS1 PDGFRA EGFR IGF1R RET MET TP53 110 RB1 56 CREBBP RTKs: receptor tyrosine kinases female never smoker biopsy cases (advanced cases) missense mutation nonsense mutation frame-shift indel inframe indel hotspot mutation copy number gain amplification

6 M: mutation, scr: Immunohistochemistry (IHC) scoring
Supplementary Figure 6 RB1 M RB scr p16 frameshift indel nonsense mutation IHC strong positive IHC weak positive M: mutation, scr: Immunohistochemistry (IHC) scoring

7 M: mutation, CN: copy number, scr: Immunohistochemistry (IHC) scoring
Supplementary Figure 7 KIT M CN scr EGFR IGF1R KDR ERBB2 FGFR1 c-Met RET ROS1 hotspot mutation frameshift indel missense mutation copy number gain amplification IHC strong positive IHC weak positive M: mutation, CN: copy number, scr: Immunohistochemistry (IHC) scoring

Download ppt "Supplementary Figure 1 A B C CD56 D E F CD56."

Similar presentations

Clinical Impression: BRONCHOGENIC CARCINOMA. Small cell lung carcinoma 20 % of lung cancer Anaplastic and highly malignant Displays neuroendocrine properties.

Clinical Impression: BRONCHOGENIC CARCINOMA. Small cell lung carcinoma 20 % of lung cancer Anaplastic and highly malignant Displays neuroendocrine properties.
Mutations. Definition mutation A mutation is a change in an organism’s DNA – Silent mutations are changes that do not result in a change to the organisms.

Mutations. Definition mutation A mutation is a change in an organism’s DNA – Silent mutations are changes that do not result in a change to the organisms.
Poor Survival and Cigarette Smoking Dosage

Poor Survival and Cigarette Smoking Dosage
Molecular Testing of lung cancer in routine practice

Molecular Testing of lung cancer in routine practice
Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.
GENOMIC ANALYSIS OF OVER 400 SARCOMAS – Gregory M. Cote – J. Butrynski, J. Shen, J. Morgan, Z. Duan, D. D’Adamo, G. Nielsen, S. George, F. Hornicek, G.

GENOMIC ANALYSIS OF OVER 400 SARCOMAS – Gregory M. Cote – J. Butrynski, J. Shen, J. Morgan, Z. Duan, D. D’Adamo, G. Nielsen, S. George, F. Hornicek, G.
HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR.

HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR.
Molecular profiling of residual TNBC after neoadjuvant chemotherapy 20150128 Yonsei Genomics Center Hanna Lee.

Molecular profiling of residual TNBC after neoadjuvant chemotherapy Yonsei Genomics Center Hanna Lee.
Chromosome Tumor samplesNormal samples Supplemental Figure 1.

Chromosome Tumor samplesNormal samples Supplemental Figure 1.
Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.
Module 4: How do unrealistic expectations confound the results of our analyses Case Studies in Bioinformatics Giovanni Ciriello

Module 4: How do unrealistic expectations confound the results of our analyses Case Studies in Bioinformatics Giovanni Ciriello
LIST OF SUPPLEMENTARY FIGURES Supplementary Figure 1: Example of KRAS-mutated LCNEC: Illustration of NGS and histopathologic features Supplementary Figure.

LIST OF SUPPLEMENTARY FIGURES Supplementary Figure 1: Example of KRAS-mutated LCNEC: Illustration of NGS and histopathologic features Supplementary Figure.
Overall (regardless of smoking Hx) Prior or current smoking Hx

Overall (regardless of smoking Hx) Prior or current smoking Hx
The Center for Personalized Diagnostics: Past, Present, and FUTURE

The Center for Personalized Diagnostics: Past, Present, and FUTURE
San Antonio Breast Cancer Symposium 2016

San Antonio Breast Cancer Symposium 2016
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations  Adi Gazdar, MD, Linda Robinson, MS, Dwight Oliver, MD,

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations  Adi Gazdar, MD, Linda Robinson, MS, Dwight Oliver, MD,
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Similar presentations

Ads by Google